FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/Highlighting the innovative approach and potential clinical impact of novel tricyclic peptide inhibitors targeting PCSK9 in treating hypercholesterolemia and coronary artery disease.
Zurück zur Forschungsbibliothek
PCSK9 inhibitorstricyclic peptidesoral bioavailability

Highlighting the innovative approach and potential clinical impact of novel tricyclic peptide inhibitors targeting PCSK9 in treating hypercholesterolemia and coronary artery disease.

May 17, 2026
Share

Quellpapier

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.

Tucker Thomas J et al.Journal of medicinal chemistry2021
Emergierende Forschung

Basiert auf emergierender Forschung. Diese Erkenntnisse sind versprechend, aber erfordern weitere Validierung.

Über diese Analyse

Diese Artikel zerlegen die Ergebnisse des obigen Quellpapiers in verständliche Sprache für die Peptidforschungscommunity. Unser Ziel ist es, das Wichtigste hervorzuheben — die praktischen Implikationen, den Stärke der Beweise und was dies für laufende Forschung bedeutet.

Novel Tricyclic Peptides: A New Chapter in PCSK9 Inhibition for Heart Health

Published: May 17, 2026 | Source: Journal of medicinal chemistry (2021) | Category: PCSK9 inhibitors, tricyclic peptides, oral bioavailability

Overview

Researchers have developed a series of novel tricyclic peptide inhibitors targeting PCSK9, which could offer significant advancements in the treatment of hypercholesterolemia and coronary artery disease. These new compounds are highly potent and can be taken orally, marking a promising step forward in peptide therapy.

Study Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that regulates cholesterol levels by controlling the number of LDL receptors on liver cells. High levels of PCSK9 reduce the body's ability to clear low-density lipoprotein (LDL), commonly known as "bad" cholesterol, leading to an increased risk of heart disease. Previous research has shown that inhibiting PCSK9 can lower LDL cholesterol and improve cardiovascular outcomes. However, existing inhibitors often require injection or have limited oral bioavailability.

What the Research Found

The study reviewed by Tucker et al. focuses on a series of novel tricyclic peptide inhibitors designed to target PCSK9 more effectively than previous generations of drugs. These new peptides are highly potent and demonstrate excellent oral bioavailability, which is crucial for patient compliance and ease of use. The research highlights the structural modifications made to enhance potency and stability in vivo.

What This Means for Peptide Users

The development of these novel tricyclic peptide inhibitors could lead to more effective treatments for hypercholesterolemia and coronary artery disease that are easier for patients to manage. Oral administration is a significant advantage over existing injectable therapies, potentially increasing patient adherence and improving long-term outcomes.

Limitations and Caveats

As this paper is a review rather than presenting new experimental data, the findings rely heavily on preclinical studies. The lack of clinical trial outcomes means that the true efficacy and safety profiles in human patients remain to be determined. Additionally, while promising, these peptides must undergo rigorous testing before they can be considered for widespread use.

How This Compares to Previous Research

Previous research has established PCSK9 inhibitors as a valuable therapeutic option but highlighted challenges such as limited oral bioavailability and the need for frequent injections. The novel tricyclic peptide inhibitors discussed in this review address these issues, offering a potential breakthrough that could significantly enhance patient care.

Our Analysis

PeptideVault views this study positively due to its innovative approach and promising findings regarding the development of next-generation PCSK9 inhibitors. However, it is crucial to acknowledge that further clinical validation is necessary before definitive conclusions can be drawn about their efficacy and safety in humans.

Key Takeaways

  • The novel tricyclic peptide inhibitors represent a significant advancement in PCSK9 inhibition with high potency and oral bioavailability.
  • These peptides could improve patient compliance by offering an alternative to injectable therapies for managing hypercholesterolemia and coronary artery disease.
  • Further clinical trials are needed to confirm the safety and efficacy of these new compounds.

Original Source

Citation: Tucker Thomas J, Embrey Mark W, Alleyne Candice et al. (2021). A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.. Journal of medicinal chemistry. DOI: 10.1021/acs.jmedchem.1c01599

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Bearbeitungsnotiz

Diese Analyse wurde vom Peptide Contacts-Forscherteam erstellt. Wir ermutigen Leser, die volle Quellpapier für vollständige Methoden und Daten. Die ursprüngliche Veröffentlichung ist auf PubMed.

Comments

Sign in to join the discussion

Diese Analyse basiert auf peer-bewerteter Forschung zur Bildungszwecke. Sie bildet keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Peptidbasierte Therapie verwenden.